Clinical Trial Update: Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated the highest safe inhaled dose of BAY 1211163, an sGC activator, in patients with Acute Respiratory Distress Syndrome. The trial was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• BAY 1211163

Snippet

Sponsor: Bayer | Conditions: Acute Respiratory Distress Syndrome | Phase 1 | Status: TERMINATED